Stock Detail
DEPOMED INC
Drug Manufacturers Other
DEPO @ Yahoo Finance | DEPO Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $4.80 | $4.97 | $-0.15 | -3.03% | 0.00 | $4.95 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $4.88 | $4.79 | 479,721 | 265.92M | 747,465.67 | 3.11 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 5.03 | 4.91 | 4.85 | 4.73 | 4.67 |
Stock Profile
Depomed, Inc., a development stage company, develops pharmaceutical products based on its proprietary oral drug delivery technologies. Its primary oral drug delivery system, Gastric Retention (GR) System offers orally administered and conveniently dosed drug therapy that provides continuous and controlled delivery of a drug over a multihour period. The company's products principally comprise Glumetza for the treatment of Type II diabetes; Proquin for treatment of urinary tract infections; and Gabapentin GR for adjunctive therapy for epileptic seizures and postherpetic pain. Its products under development include Furosemide GR for the treatment of severe congestive heart failure patients. Depomed, through collaboration agreements, also develops other product candidates for the delivery of large molecules, such as antisense compounds from the GR System; and a combination product comprising its Glumetza for Type II diabetes. It has collaboration agreements with Biovail Laboratories Incorporated; LG Life Sciences, Ltd.; New River Pharmaceuticals, Inc.; and AVI BioPharma, Inc. The company was founded by John W. Shell. Depomed was incorporated in 1995 and is based in Menlo Park, California.